Antibiotic Resistance | The Center For Disease Dynamics, Economics & Policy (CDDEP) Read More »
To better communicate the problem of antimicrobial resistance (AMR), researchers at The Center For Disease Dynamics, Economics & Policy (CDDEP) developed the Drug Resistance Index (DRI), which provides a snapshot of the effectiveness of antibiotic therapy by country. The DRI resembles stock market indices and combines antibiotic consumption measurements with resistance data to help compare […]
AMR Solutions Newsletter | John H. Rex, MD Read More »
John H. Rex is a physician and drug developer with more than 30 years of development and policy experience focused on antimicrobial agents. He has extensive experience overseeing antifungal and antibacterial agents through all development phases, and is an active contributor to global efforts to enable the development of new agents. Subscribe to his AMR
REVIVE – Advancing Antimicrobial R&D Read More »
As well as the growing alarm over drug-resistance, there is also the concern over the slow rate in the discovery and development of new treatments. Furthermore, the abandonment of antimicrobial research and development by many companies and academic laboratories has led to the risk of valuable knowledge in the field being lost. To address this
The Global Antibiotic Research and Development Partnership (GARDP) Read More »
The Global Antibiotic Research and Development Partnership (GARDP) is a not-for-profit organization developing new treatments for drug-resistant infections that pose the greatest threat to health. GARDP works with partners to ensure sustainable access to treatments, promoting responsible use and affordability to all in need. Learn more on the GARDP website.
Antibiotic Resistance Project | The Pew Charitable Trusts Read More »
Antibiotics are one of the greatest success stories in modern medicine. Although we associate them with treating acute infections, these drugs underpin much of health care—from routine surgical procedures to organ transplants and cancer treatment. Unfortunately, the history of antibiotics is a race between innovation and resistance. As innovative science furnishes novel drugs, bacterial evolution
CARB-X: Combatting Antibiotic Resistance Bacteria Read More »
CARB-X is accelerating global antibacterial innovation by investing in the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Their projects represent the world’s largest pre-clinical and early development pipeline of antibiotics and other therapeutics, diagnostics, microbiome and vaccines. Since CARB-X was established in July 2016, it has invested
Drug-resistant infections kill hundreds of thousands of people every year, in all parts of the world. This burden is disproportionately higher in low- and middle-income countries. If we act now, we can turn the tide on antimicrobial resistance (AMR), save millions of lives and safeguard the medical progress of the past hundred years for future
The David Braley Centre for Antibiotic Discovery (DBCAD) Read More »
Successfully addressing the global antimicrobial resistance (AMR) crisis requires a creative, strategic, and multifaceted approach. As a world-leading academic institution in AMR research and innovation, McMaster University has leveraged its impact through the David Braley Centre for Antibiotic Discovery (DBCAD). This Centre provides McMaster’s team of distinguished scientists with the opportunity to translate new knowledge
Highlights of the 2019 ICARe course edition.
Highlights of the 2018 ICARe course edition.
